Imiquimod, pegyliertes Interferon-?-2b und Interleukin-2 in der Behandlung kutaner Melanommetastasen
- 1 February 2004
- journal article
- case report
- Published by Springer Nature in Die Dermatologie
- Vol. 55 (2) , 176-181
- https://doi.org/10.1007/s00105-003-0625-z
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Topical Imiquimod in the Treatment of Metastatic Melanoma to SkinArchives of Dermatology, 2003
- Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanomaMelanoma Research, 2003
- Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusionBritish Journal of Dermatology, 2002
- Imiquimod: A cytokine inducerJournal of the American Academy of Dermatology, 2002
- Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: A double-blind, randomized, vehicle-controlled study*Journal of the American Academy of Dermatology, 2002
- Imiquimod, a Topical Immune Response Modifier, in the Treatment of Cutaneous Metastases of Malignant MelanomaDermatology, 2002
- U.K. guidelines for the management of cutaneous melanomaBritish Journal of Dermatology, 2002
- Effect of IFN-α on Tumor-Infiltrating Mononuclear Cells and Regressive Changes in Metastatic Malignant MelanomaJournal of Interferon & Cytokine Research, 1998
- Peritumoral appliziertes IL-2 induziert Tumorregression beim MelanomDie Dermatologie, 1994
- Immunocytochemical Analysis of the Cellular Infiltrate in Primary Regressing and Non-Regressing Malignant MelanomaJournal of Investigative Dermatology, 1991